Merck adds Lilly neuroscience veteran
Executive Summary
Lilly's global head of neuroscience research and early clinical investigation Darryle Schoepp jumps to Merck where he will serve as senior VP and franchise head of neuroscience, the company says March 5. In that role he will oversee drug discovery and development and report to Merck Research Laboratories President Peter Kim. The most advanced neuroscience product in Merck's pipeline is the Phase III insomnia agent gaboxadol...
You may also be interested in...
EU’s SCCS Finds Endocrine-Disrupting Evidence Inconclusive In UV Filter Reassessments
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
US FDA Urges COVID-19 Transmission Risk Mitigation In Cell And Gene Therapy Manufacturing
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
COVID-19: US Acted To Beat Other Countries To Next 1.25M Doses Of Regeneron Cocktail
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: